Dr. Thomas J. Imperato, MD

Dr. Imperato practices at Endoscopy Center of South Sacramento in Sacramento, California.

Dr. Imperato's NPI, 1902871684, was assigned on February 17, 2006. Dr. Imperato graduated from University of Padua College of Medicine in 1970. Dr. Imperato's California license number on file is 00A245440.

Dr. Imperato's primary practice is Endoscopy Center of South Sacramento, at 8120 Timberlake Drive #103, Sacramento, CA 95823. The practice phone is (916) 681-2350.

Dr. Imperato's primary practice is Endoscopy Center of South Sacramento in Sacramento, California. The medical group on file is Mercy Medical Group. Dmand AI also links Dr. Imperato to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Imperato practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Imperato's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Imperato is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Imperato has a license on file in California.

Dmand AI lists acid reflux, acute gastroduodenitis, chronic inflammatory bowel disease (IBD), cirrhosis of the liver, colonoscopy, gastroenteritis, gastrointestinal bleeding and hemorrhoids among the conditions Dr. Imperato treats.

CMS data shows 214 Medicare services from Dr. Imperato across 8 procedure codes in 2024, for 147 Medicare patients. Medicare paid $24,015 for them.

CMS counts 147 Medicare patients who saw Dr. Imperato in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 50% are also on Medicaid. Their average risk score is 1.35, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Imperato's median patient age at 68, with 52% women.

In 2024, Dr. Imperato wrote 438 Medicare Part D claims for 132 patients. 67% of them were for generic drugs. CMS names the drug for 326 of them, across 13 drugs with 11 or more claims each, at $219,412 in total drug cost. In 2023, CMS named 732 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Imperato for performance year 2024, reported through an alternative payment model (APM).

Dmand AI links 6 papers to Dr. Imperato. The most frequent topics are Kinetics, Liver and Sulfates. Dr. Imperato has published most often in Acta Gastroenterol Latinoam. Dr. Imperato's most frequent co-author is David Cantor, MD.

CMS Open Payments shows 261 general payments to Dr. Imperato from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $1,076.

Dmand AI lists 1 award for Dr. Imperato, most recently CMS Stage 1 EHR in 2012.

Dr. Imperato graduated from University of Padua College of Medicine in 1970.

Dr. Imperato is in network with 15 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.